MARKET

AIKI

AIKI

Aikido Pharma Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

5.84
+0.18
+3.18%
After Hours: 5.81 -0.03 -0.51% 17:25 06/24 EDT
OPEN
5.66
PREV CLOSE
5.66
HIGH
5.89
LOW
5.64
VOLUME
62.03K
TURNOVER
0
52 WEEK HIGH
17.51
52 WEEK LOW
4.300
MARKET CAP
30.67M
P/E (TTM)
-4.5579
1D
5D
1M
3M
1Y
5Y
BRIEF-Aikido Reports Formation Of New Financial Services Subsidiary
reuters.com · 2d ago
AIkido Inc. Announces the Formation of a New Financial Services Subsidiary
AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") announced the formation of a wholly owned subsidiary with the purpose of making strategic investments and acquisitions across the fintech and financial services industries. The new subsidiary is...
PR Newswire · 2d ago
AIkido Pharma Forms Financial Services Unit
MT Newswires · 2d ago
BRIEF-Press Release - Significant Investor In Aikido Pharma Urges Board To Commit To Sell Assets
reuters.com · 5d ago
Significant Investor in AIkido Pharma Urges Board to Commit to Sell Assets and Return Capital to Stockholders
The Board and Management Clearly Have Lost the Confidence of Stockholders Concerned that Allowing the Status Quo to Continue Will Result in More Insider Dealing and Destruction of Stockholder Value Believes the Commencement of an Orderly Process to Sell Co...
GlobeNewswire · 5d ago
AIkido Pharma investor Shalom Auerbach issues open letter to the company
Shalom Auerbach, a shareholder of AIkido Pharma (NASDAQ:AIKI) with an about 3.4% stake in the biotech, on Tuesday issued a letter to the company's board of directors. Auerbach believes the
Seekingalpha · 06/07 20:48
BRIEF-Shalom Auerbach - Issues Open Letter To Board Of Directors Of Aikido Pharma
reuters.com · 06/07 20:40
Significant Investor In Aikido Pharma Issues Open Letter To Board Of Directors
Significant Investor in AIkido Pharma Issues Open Letter to Board of Directors Continued Destruction of Value and Poor Corporate Governance is Unacceptable   Company Needs a Clear Business Plan to Create
Benzinga · 06/07 20:37
More
No Data
Learn about the latest financial forecast of AIKI. Analyze the recent business situations of Aikido Pharma Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

0.00%Strong Buy
100.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average AIKI stock price target is 34.00 with a high estimate of 34.00 and a low estimate of 34.00.
High34.00
Average34.00
Low34.00
Current 5.84
EPS
Actual
Estimate
-0.95-0.71-0.48-0.24
Q2 2021
    0
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 26
Institutional Holdings: 439.63K
% Owned: 8.37%
Shares Outstanding: 5.25M
TypeInstitutionsShares
Increased
6
6.72K
New
7
20.91K
Decreased
5
31.95K
Sold Out
7
22.23K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.67%
Pharmaceuticals & Medical Research
+2.48%
Key Executives
Non-Executive Chairman/Independent Director
Robert Vander Zanden
Chief Executive Officer/Chief Financial Officer/Chief Accounting Officer/Director
Anthony Hayes
Director
Robert Dudley
Director
Paul LeMire
Director
Kyle Wool
Director
Soo Yu
Independent Director
Gregory Blattner
Independent Director
Tim Ledwick
No Data
No Data
About AIKI
AIkido Pharma Inc. is a biotechnology company. It is focused on developing a diverse portfolio of small-molecule anti-cancer therapeutics. Its pipeline consists of patented technology from universities and researchers. Its oncology therapeutics include treatments for pancreatic cancer, acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). It is focused on the treatment of three different cancers and multiple types of viral infections. It is also developing a spectrum of antiviral platform that may potentially inhibit replication of multiple viruses including Influenza virus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV), Middle East respiratory syndrome coronavirus (MERS-CoV), Ebolavirus and Marburg virus. Its subsidiaries include Nuta Technology Corp., Spherix Portfolio Acquisition II, Inc., Guidance IP, LLC, Directional IP, LLC, Spherix Management Services, LLC (SMS), Spherix Delaware Merger Sub Inc., Spherix Merger Subsidiary, Inc and NNPT, LLC.

Webull offers kinds of Aikido Pharma Inc stock information, including NASDAQ:AIKI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AIKI stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading AIKI stock methods without spending real money on the virtual paper trading platform.